Hyloris Pharmaceuticals SA: Hyloris Announces Launch of Maxigesic IV in the U.S. and approval In Canada finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Maxigesic® IV, a Potent Non-opioid Painkiller, Marketed in the U.S. under the Tradename Combogesic® IVMaxigesic® IV.
Hyloris Enrolls First Patient In Phase 3 Clinical Trial For Its Proprietary Mouth Rinse To Control Incidences Of Bleeding Related To Dental Procedures menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 291 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information – Hyloris Pha
Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms.